Acorah Software Products - Accounts Production 19.2.450 false true true false 21 May 2025 31 March 2026 31 March 2026 16464254 Dr S Cartwright iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 16464254 2025-05-20 16464254 2026-03-31 16464254 2025-05-21 2026-03-31 16464254 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2026-03-31 16464254 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-05-21 2026-03-31 16464254 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-05-20 16464254 frs-core:ShareCapital 2026-03-31 16464254 frs-core:RetainedEarningsAccumulatedLosses 2026-03-31 16464254 frs-bus:PrivateLimitedCompanyLtd 2025-05-21 2026-03-31 16464254 frs-bus:FilletedAccounts 2025-05-21 2026-03-31 16464254 frs-bus:SmallEntities 2025-05-21 2026-03-31 16464254 frs-bus:AuditExempt-NoAccountantsReport 2025-05-21 2026-03-31 16464254 frs-bus:SmallCompaniesRegimeForAccounts 2025-05-21 2026-03-31 16464254 frs-bus:Director1 2025-05-21 2026-03-31 16464254 frs-countries:EnglandWales 2025-05-21 2026-03-31
Registered number: 16464254
Fearless Labs Ltd
Unaudited Financial Statements
For the Period 21 May 2025 to 31 March 2026
Harpers Accountancy LLP
PO Box 293
Lewes
BN7 9PG
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 16464254
31 March 2026
Notes £ £
FIXED ASSETS
Intangible Assets 4 28,276
28,276
CURRENT ASSETS
Debtors 5 441
Cash at bank and in hand 5,600
6,041
Creditors: Amounts Falling Due Within One Year 6 (42,413 )
NET CURRENT ASSETS (LIABILITIES) (36,372 )
TOTAL ASSETS LESS CURRENT LIABILITIES (8,096 )
NET LIABILITIES (8,096 )
CAPITAL AND RESERVES
Called up share capital 7 1
Profit and Loss Account (8,097 )
SHAREHOLDERS' FUNDS (8,096)
Page 1
Page 2
For the period ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Dr S Cartwright
Director
08/09/2026
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Fearless Labs Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 16464254 . The registered office is B1 Vantage Business Park, Old Gloucester Road, Hambrook, Bristol, BS16 1GW.
Fearless Labs Limited was incorporated on 21 May 2025 and thus the financial statements represents a period of 10 months and 10 days.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.
2.3. Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services
provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair
value of consideration takes into account trade discounts, settlement discounts and volume rebates.
2.4. Research and Development
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits, and hence all expenditure on research is recognised as an expense when it is incurred.
Intangible assets are recognised from the development phase of a project if, and only if, certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised to profit or loss on a straight-line basis over their expected useful economic lives, which range from 3 to 5 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
Amortisation of capitalised development costs begins when the related asset is available for use, being when it is in the condition necessary for it to be capable of operating in the manner intended by management. Costs are reviewed for indicators of impairment at each reporting date, including while the asset remains under construction and not yet amortising.
2.5. Financial Instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12
‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Page 3
Page 4
3. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
4. Intangible Assets
Development Costs
£
Cost
As at 21 May 2025 -
Additions 28,276
As at 31 March 2026 28,276
Net Book Value
As at 31 March 2026 28,276
As at 21 May 2025 -
5. Debtors
31 March 2026
£
Due within one year
Other debtors 441
6. Creditors: Amounts Falling Due Within One Year
31 March 2026
£
Other creditors 42,413
7. Share Capital
31 March 2026
£
Allotted, Called up and fully paid 1
Page 4